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Abstract
The broad spectrum of applications of three-dimensional printing (3D printing,
3DP) has attracted the attention of researchers working in diverse fields. In
pharmaceutics, the main idea behind 3D printing products is to design and develop
delivery systems that are suited to an individual’s needs. In this way, the size, appear-
ance, shape, and rate of delivery of a wide array of medicines could be easily adjusted.
The aim of this chapter is to provide a compilation of the 3D printing techniques, used
for the fabrication of oral drug delivery systems, and review the relevant scientific
developments in particular those with modified-release characteristics.
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1. Introduction
3D printing is an object fabrication technique based on the sequential deposition
of layers of materials. Using a computer-aided design (CAD) software, structures of
various sizes and shapes can be produced. This method has found application in
many sectors, from industrial engineering to personalized biomaterials and devices
in medicine [1, 2]. Within the pharmaceutical field, 3D printing can produce small
batches of medicinal products, with tailored dosages, shapes, sizes, and release
characteristics [3]. These advantages of 3D printing facilitate the efforts towards
personalized therapies. The need for the modification of a dose that will fit better a
patient’s individual needs arises from differences in the patient’s age, weight, and
severity of disease(s) [4]. Even though there are great advancements in drug
administration methods, the orally administered drugs remain the most preferred
choice by patients due to the fact that it is relatively safe, very convenient and cost-
effective. The preference on oral solid pharmaceutical forms, especially tablets, has
rendered the personalization of oral solid dosage forms a step forward in the
healthcare system [4].
2. History
The increasing applications of 3D printing have made it a well-accepted concept
at present times. Charles Hull is considered the pioneer of 3D printing, as he
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developed, patented, and commercialized the first equipment for the 3D printing of
objects in 1983. Hull’s 3D printing technique was based on stereolithography. It
consisted of a laser that moved across the surface of a liquid resin, curing it. This
process was repeated layer by layer many times until the desired shape was formed.
In 1988, Charles Deckard filed a patent for selective laser sintering. In this process, a
laser beam is scanned over a powder bed to sinter or fuse the powder that is placed
on a powder bed. The powder bed is then lowered, fresh powder is spread, and the
process is repeated to produce a solid object. The un-bonded is then removed, and
the structure can be further treated, for example, with heat, to enforce the bonding.
In 1989, Scott Crump filed a patent on fused deposition modeling. Using this
technique, the object is formed by depositing layers of solidifying materials (self-
hardening waxes, thermoplastic resins, and molten metals) until the desired shape
is formed [5, 6]. In 2015, the FDA approved Spritam®, the first 3D-printed pre-
scription drug product to treat partial onset seizures, myoclonic seizures, and
primary generalized tonic-clonic seizures. Since then, many innovations have been
evolved using the 3DP technology.
3. Advantages and limitations
The oral dosage form production by the 3DP processes has many advantages
specially for customizing drug delivery. The active ingredient can be included in the
dosage form as per each patient requirements to achieve a personalized dose and
release pattern. 3D printing aids also in achieving multidrug combinations with
complex release profiles [7]. On-demand production and tailor-made products with
specific geometries, designs, and shape forms can be achieved which otherwise
would be difficult with the conventional tableting. Even though there has been
intense research to circumvent the 3D printing flaws, this new technology has still
some limitations. Few 3D printing techniques may produce relatively porous struc-
tures and uneven shapes of dosage forms [6]. When fused deposition modeling
technique is utilized, the use of only thermostable drugs and the few available
compatible excipients is a limiting step. Also, with stereolithography, the challenge
lies on the potential drug degradation due to the exposure to UV light that induces
polymerization reaction [5].
4. Various techniques used in 3D printing
Irrespective of the 3D printing technique employed, the process follows three
basic steps: the creation of a computer-aided design file; followed by its transfor-
mation to a rapid prototyping stereolithography file (.stl), which describes the
surface geometry of the 3D object; and finally, its conversion to a machine specific
code (.gcode) which is recognized by the 3D printer machine and creates the final
object [8] (Figure 1).
There are various ways to classify the 3D techniques, according to the additive
process followed, the form of the raw materials used, the mechanism of layering, or
even the kind of printing heads utilized [9]. Figure 2 illustrates the different 3D
Figure 1.
The basic steps of 3D printing process.
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printing techniques categorized by the raw materials employed. Among them,
stereolithography, selective laser sintering, binder jetting, and fused deposition
modeling are the most used techniques in the literature for the production of
pharmaceutical dosage forms [10].
Stereolithography employs raw materials in the liquid form, such as photosensi-
tive/photopolymerizable liquid resins. A high-energy light source like ultraviolet
irradiation solidifies the liquid resins, creating the 3D object [6]. Among the
advantages of this technique are the high accuracy and good surface quality of the
object. This method has been widely used for implant design and manufacture as
well as for creating accurate 3D models acquired from various anatomical scans
of a patient.
Selective laser sintering (SLS) technique utilizes raw materials in a powder form,
and the laser used melts and bonds the layers of material powders together. SLS
has been used for the manufacturing of artificial tissue.
On the other hand, binder jetting technique, also called drop-on-demand inkjet
printing or 3D printing, is able to create 3D objects from powder materials by
depositing liquid binder droplets onto a powder substrate and sticking the particles
together [9, 10]. This technique along with the continuous inkjet printing belongs to
the printing-based inkjet systems and has been utilized for the fabrication of
implants and solid dosage forms, such as the first commercially printed tablet
Spritam®.
Finally, the most widely spread technique is the fused deposition modeling
(FDM), and it belongs to the nozzle-based printing techniques. FDM is character-
ized by the use of thermoplastic polymers that pass through a pre-heated printing
head and is melted and extruded through a precise nozzle with a specific diameter.
In contact with the cold printing surface, the polymers solidify and thus create the
3D object. A variation of this type of 3D printing technique is the semisolid extru-
sion system, in which semiconductors (gels, ointments) are printed through a
syringe-shaped extruder [10]. In the recent years, these techniques have been
extensively used for the research and development of various pharmaceutical forms
such as hydrogels or coated solid dosage forms [11].
Figure 3 depicts the main additive manufacturing technologies which either
experimentally or industrially have been used for the manufacturing of pharma-
ceutical dosage forms.
Figure 2.
3D printing technique categorization.
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5. Recent accomplishments in modified-release 3D-printed tablets
Orodispersible, sublingual, fast-dissolving drug delivery formulations that rap-
idly disintegrate in the oral cavity or immediate-release tablets by 3D printing have
been produced [12–15].
Multipurpose therapeutic systems offering tailored combinations of drugs, drug
doses, and the desired release kinetic properties have attracted increasing attention,
due to the advantages that these personalized pharmaceutical products could offer.
In this respect, many scientists have designed modified-release oral dosage medi-
cines, using 3D printing. The drug release from modified-release formulations is
changed on purpose from that of an immediate-release formulation to achieve a
preferred therapeutic goal. The applications of 3DP on modified per oral drug
delivery are summarized in Table 1.
Genina et al. [16] have shown that coupling fused deposition modeling 3D
printing with the hot-melt extrusion offers a new method for manufacturing
tailored-dosage medicines, with modified-release properties. In detail an oral dual-
compartmental dosage unit (dcDU) has been designed, and the in vitro and in vivo
release profiles of an antitubercular drug combination of rifampicin and isoniazid
have been evaluated. These two active ingredients are considered as first-line ther-
apy for tuberculosis but interact negatively with each other upon simultaneous
release in acidic environment. This was circumvented by the compartmentalization
of rifampicin and isoniazid into sealable compartments of 3D-printed dual-
compartmental dosage units. This novel delivery system was characterized with
focus on microscopic verification of the designed attributes, the modulation of drug
release from dcDUs, and the pharmacokinetic profile of dcDUs in rats. In another
study [17] an oral solid dosage form was developed by employing the fused deposi-
tion modeling, using a custom-built filament consisted of polyvinyl alcohol, man-
nitol, and hydrochlorothiazide, as a model drug, co-formulated via hot-melt
extrusion. The dissolution studies performed demonstrated zero-order release
kinetics. In another study [18], hot-melt extrusion and fused deposition modeling
were used to produce different shaped tablets (cube, pyramid, cylinder, sphere, and
torus) containing acetaminophen. It was found that drug’s release was not
Figure 3.
Basic 3D printing techniques deployed for the manufacturing of pharmaceutical dosage forms.
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Release
behavior*
Dosage form API(s) Excipient(s) Technique Ref.
Modified Dual-
compartment
tablet
Rifampicin and
isoniazid
Polyethylene oxide,
polylactic acid (PLA),
polyvinyl alcohol
(PVA)
FDM/HME [16]
Three-
compartment
tablet
Hydrochlorothiazide Partially hydrolyzed
PVA (Mowiol®4–88),
mannitol
FDM/HME [17]
Tablets of
various
shapes
Paracetamol Polyvinyl alcohol FDM/HME [18]
Caplets Budesonide Polyvinyl alcohol,
Eudragit® L 100,
triethyl citrate, talc,
isopropanol-water
solution
FDM/HME and
fluid bed coating
[19]
Tablets 5-Aminosalicylic acid
and 4-aminosalicylic
acid
Polyvinyl alcohol FDM [20]
Caplets Paracetamol or
caffeine
Polyvinyl alcohol FDM [21]
Tablets 4-Aminosalicylic acid
and paracetamol
Polyethylene glycol
diacrylate, diphenyl
(2,4,6-
trimethylbenzoyl)
phosphine oxide, and
(PEG 300)
Stereolithography [22]
Tablets Acetaminophen Methocel™ E50,
polyvinylpyrrolidone
(Povidone K30), ethyl
cellulose, Eudragit®
RS 100, stearic acid,
sodium lauryl sulfate,
fluorescein, colloidal
silicon dioxide
Inkjet printing [23]
Extended Tablets Acetaminophen Benecel™ HPMC E5
and Aqualon™ EC N14
with either Klucel™
HPC EF and LF,
Soluplus®, or
Eudragit® L 100
FDM/HME [24]
Tablets Theophylline Eudragit RL 100, RS
100, and E and
hydroxypropyl
cellulose (SSL grade),
triethyl citrate
FDM/HME [25]
Tablets Prednisolone Polyvinyl alcohol FDM [26]
Tablets Fluorescein Polyvinyl alcohol FDM [27]
Controlled Tablets Fenofibrate White beeswax Inkjet printing [28]
Sustained Polypill Captopril,
nifedipine, and
glipizide
Hydroxypropyl
methylcellulose
(HPMC 2208),
polyethylene glycol
(PEG 6000),
Extrusion [29]
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Release
behavior*
Dosage form API(s) Excipient(s) Technique Ref.
tromethamine, lactose,
sodium chloride, D-
mannitol,
croscarmellose sodium,
microcrystalline
cellulose, sodium
starch glycolate,
hydroxypropyl
methylcellulose
(Methocel™), cellulose
acetate
Delayed DuoCaplet Paracetamol and
caffeine
Polyvinyl alcohol FDM/HME [30]
Tablets Paracetamol Hypromellose acetate
succinate (HPMC LG,
MG, HG),
methylparaben NF
grade, magnesium
stearate
FDM/HME [31]
Shell-core
tablets
Theophylline,
budesonide, and
diclofenac sodium
Core:
Polyvinylpyrrolidone,
triethyl citrate, talc or
tribasic phosphate
sodium, and API
Shell: Eudragit® L
100–55, triethyl citrate,
and talc
Dual FDM/HME [32]
Pulsatile Two-
compartment
capsular
device
Acetaminophen Polylactic acid,
polyvinyl alcohol,
hydroxypropyl
methylcellulose
(HPMC), HPMC
acetate succinate,
polyvinyl alcohol-
polyethylene glycol
graft copolymer,
glycerol, polyethylene
glycol (PEG 400,
PEG8000), blue and
yellow dye-containing
formulations
(Kollicoat®IR Brilliant
Blue and
Kollicoat®IRyellow)
FDM/HME
injection molding
[33]
Immediate
/sustained
Bilayer tablet Guaifenesin Hydroxypropyl
methylcellulose
(HPMC 2910 & 2208),
poly(acrylic acid),
microcrystalline
cellulose, sodium
starch glycolate
Extrusion [34]
Polypill Aspirin,
hydrochlorothiazide,
ramipril, pravastatin
sodium, atenolol
Cellulose acetate, D-
mannitol, polyethylene
glycol (PEG 6000)
sodium starch
glycolate,
Polyvinylpyrrolidone
Extrusion [35]
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dependent on the tablet surface area, but on the surface-area-to-volume ratio,
indicating the effect of the shape on the release profile. The results showed that the
tablets of similar mass showed little difference in dissolution profiles that could be
explained by the erosion-mediated process that controlled the drug release. Tablets
of various shapes may alter the drug dissolution profiles and can aid in the design of
new dosage forms with specific pharmacokinetic characteristic targeted to different
sites in the gastrointestinal track. Fused deposition 3D printing technology along-
side with hot-melt extrusion and fluid bed coating was used to fabricate modified-
release budesonide dosage forms. The drug was loaded into polyvinyl alcohol fila-
ments which were then engineered into capsule-shaped tablets and coated with a
layer of enteric polymer. The dissolution studies showed that the drug release from
the caplet formulation started at the small intestine and continued in a sustained
manner throughout the large intestine and colon [19]. The same group of
researchers has also produced tablets containing as model drugs the two
aminosalicylic acid isomers, 5-aminosalicylic acid and 4-aminosalicylic acid, using
fused deposition modeling. The results indicated that the release profiles obtained
could be easily modified by the proper selection of the printing parameters [20].
Furthermore, fused deposition modeling was used to produce acetaminophen or
caffeine caplets from polyvinyl alcohol filaments. The dissolution tests performed in
biorelevant bicarbonate media revealed distinctive modified-release profiles, which
were dependent on drug solubility and drug loading. The results indicated that the
drug release can be faster from formulations incorporating the drug with higher
solubility and higher loading [21]. Additionally, Wang et al. [22] managed to for-
mulate modified-release tablets of paracetamol and 4-aminosalicylic acid using
polyethylene glycol diacrylate as monomer and diphenyl (2,4,6-trimethylbenzoyl)
phosphine oxide as a photoinitiator in stereolithographic 3D printing. Also, in
another study [23], researchers employed the powder bed/jetting method to con-
struct a methacrylic or ethylcellulose matrix tablet to achieve a modified release of
acetaminophen. Erosion and in vitro dissolution studies in ethylcellulose-containing
tablets indicated that the drug was released via a two-dimensional surface erosion
mechanism and 98% of the drug could be released linearly in 12 h. Tablets with
other release-retardation materials, such as sodium lauryl sulfate, stearic acid, and
Release
behavior*
Dosage form API(s) Excipient(s) Technique Ref.
(Povidon K30),
hydroxypropyl
methylcellulose
(Methocel™
K100MCR), lactose
Immediate/
extended
Tablets Chlorpheniramine
maleate
Microcrystalline
cellulose powder,
Eudragit® E 100,
RLPO
Inkjet [36]
Enteric
dual
pulsatory
Tablets Diclofenac Avicel PH301, lactose,
Eudragit® L 100,
Inkjet [36]
Dual
pulsatory
Tablets Diclofenac Eudragit® E 100 and L
100
Inkjet [36]
*The release behavior reported as defined by the author.
Table 1.
An overview of the 3DP technique applications in modified per oral drug delivery (FDM, fused deposition
modeling; HME, hot-melt extrusion).
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Eudragit RS-100, showed similar release-retardation effects by different release
mechanisms.
Zhang et al. fabricated solid-dispersion filaments with acetaminophen dissolved
or dispersed in a polymer matrix by hot-melt extrusion technology, which was
suitable for fused deposition modeling-based 3D printing. The 3D printed tablets
showed more extended drug release rates than the directly compressed tablets [24].
In another study [25], using the same methods, scientists presented a flexible dose
tablet system, suitable for both immediate and extended-release tablets. As excipi-
ents three methacrylic polymers (Eudragit RL, RS, and E) as well as a cellulose-
based material (hydroxypropyl cellulose, HPC SSL) were used, while theophylline
was used as a model drug substance. Moreover, in another report [26], the feasibil-
ity of using a fused deposition modeling-based 3D printer to fabricate extended-
release tablets, using prednisolone loaded poly(vinyl alcohol) filaments, and to
control its release was investigated. The results indicated that the in vitro drug
release was extended up to 24 h, showing that the fused deposition modeling is a
promising method to control the dose of extended-release tablets. Moreover in
another work, polyvinyl alcohol filaments have been loaded with fluorescein as a
model drug, by swelling of the polymer in ethanolic drug solution, and 10-mm-
diameter tablets of polyvinyl alcohol/fluorescein using fused deposition modeling
3DP were printed. The dissolution tests that were conducted in modified Hank’s
buffer indicated controlled-release profiles [27].
Kyobula et al. [28] have prepared drug-loaded solid dosage forms with complex
geometries such as honeycomb based, using hot-melt 3D inkjet printing. The model
drug used was fenofibrate, and the relevant studies indicated controlled release.
This study verified an alternative production approach for solid dosage forms with
different geometry, which could achieve various release profiles for personalized
drug products.
Khaled et al. [29] have employed 3D extrusion-based printing as a technique for
the production of multi-active tablets with well-defined and separate controlled-
release profiles for three different drugs, namely, captopril, nifedipine, and
glipizide. This “polypill” incorporated an osmotic pump for captopril and sustained
release compartments for nifedipine and glipizide. The dissolution testing showed
that the captopril portion exhibited the expected zero-order drug release from an
osmotic pump, while the others showed either first-order release or Korsmeyer-
Peppas release kinetics dependent on the active/excipient ratio used.
Goyanes et al. [30] used the fused deposition modeling 3D printing to fabricate
novel oral drug delivery systems with paracetamol and caffeine filaments of poly
(vinyl alcohol), with the intent of applying this process to the production of per-
sonalized products, tailored at the point of dispensing or use. The design included a
multilayer device, with each layer containing drug, whose identity was different to
the drug in the adjacent layers, and a two-compartment device, comprising of a
caplet in caplet (DuoCaplet), with each compartment containing a different drug.
The drug release tests in biorelevant bicarbonate media showed unique drug release
profiles depending on the macrostructure of the devices. In the multilayer device
incorporating two drugs, the drug release rate was similar for both drugs but faster
when the drug loading was higher. In DuoCaplets the drug incorporated in the
external layer was released first, and there was a lag time until the release of the
drug contained in the core, depending on the characteristics of the external layer.
Moreover, the same group [31] used the fused deposition modeling and the hot-
melt extrusion to generate paracetamol-loaded tablets from filaments produced
from three different grades of hypromellose acetate succinate. The dissolution tests
showed that the drug release from the tablets depended on the polymer composi-
tion, the drug loading, and the internal structure of the formulations. Especially, all
8
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HPMCAS-based tablets showed initial delayed release in the gastric medium and in
the intestinal conditions, and the drug release was faster from the tablets prepared
using polymers with a lower pH threshold. These results confirm that the fused
deposition modeling 3DP makes possible the production of delayed-release
printlets, without the need of enteric coating. Okwuosa et al. [32] managed to
fabricate shell-core delayed-release tablets of theophylline, budesonide, and
diclofenac sodium with dual fused deposition modeling 3D printing and hot-melt
extrusion. For the core structure, filaments consisting of the polymer (PVP), plas-
ticizer (triethyl citrate), filler (talc) or tribasic phosphate sodium, and the active
ingredient were created with hot-melt extrusion. While for the shell, Eudragit
L100–55, triethyl citrate, and talc were used. The created filaments were then used
for the printing of caplets containing the active ingredient in the core, while the
shell serves as an enteric coating. This study demonstrated the potential of fabri-
cating patient-specific pH-responsive tablets in one step. In another article, Maroni
et al. [33] have reported on the manufacture of a two-compartment capsular device
conveying incompatible drugs or differing drug formulations using the fused depo-
sition modeling and injection molding. Through the assembly of compartments that
had different wall thickness and/or composition, the drug release could be charac-
terized as pulsatile.
Khaled et al. [34] used the extrusion-based 3DP for the preparation of
guaifenesin bilayer tablets with an immediate-release and a sustained-release layer.
Drug release kinetics indicated Fickian diffusion drug release through the hydrated
HPMC gel layer. The same group of researchers [35] used the same technique for
the production of a novel complex geometry “five-in-one” polypill. The drugs,
aspirin, hydrochlorothiazide, ramipril, and pravastatin atenolol, were physically
separated in the polypill to avoid incompatibility issues and allow maximum flexi-
bility. Release studies revealed immediate and sustained drug release mechanisms.
A research group formulated immediate/extended-release tablets, which were
composed of two drug-containing sections of different pH-based release mecha-
nisms. The pulsed release of the model drug, chlorpheniramine maleate, took place
after a lag time of 10 min followed by extended release of the compound over a
period of 7 h. Furthermore, enteric dual pulsed-release tablets were constructed and
the dissolution profiles showed that two pulses of diclofenac sodium, released, one
immediately at t = 1 h and the second pulse began after a lag time of 4 h. The same
group of researchers [36] also fabricated dual pulsed-release tablets, where one
section eroded immediately in the acidic environment stage releasing diclofenac
during the first 30 min, while the second section eroded 5 h later, at higher pH values.
6. Conclusions
The present chapter offers a review of the 3D-printed modified-release oral solid
pharmaceutical formulations that have been created up to date. It aims at demon-
strating the potential role of this technology in the tailored manufacture of phar-
maceutical products. Even though 3DP has been introduced since the 1980s, there is
still a lot of exploration in this field, especially for the creation of materials suitable
for pharmaceutical and medical applications. One of the ongoing researches in the
area is the 3DP of new, versatile materials that have the ability to change their
properties under the influence of external factors or over time. The structural
modification over time or otherwise called the fourth dimension, created a new
term called “4D printing” [37]. In oral dosage forms, this technology allows the
modification of drug delivery, since the timely release profile can be triggered by
stimuli, such as pH, temperature, enzymes action, and time [38].
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